Prevention of acute radiation-induced rectal toxicity by amifostine: Efficacy and evaluation of objective and subjective endpoints for radiation therapy-induced mucositis

Supportive Cancer Therapy

Volumn 4, Issue 1, 2006, Pages 23-29

  Kouloulias, Vassilis ^a,b   Kouvaris, John ^c   Mystakidou, Kyriaki ^c   Kelekis, Nikolaos ^b  

^a NATIONAL AND KAPODISTRIAN UNIVERSITY OF ATHENS   (Greece)

^b UNIVERSITY OF ATHENS   (Greece)

^c UNIVERSITY OF ATHENS   (Greece)

Author keywords

Pelvic irradiation; Rectal mucosa; Rectosigmoidoscopy; Toxicity scale

Indexed keywords

2 (3 AMINOPROPYLAMINO)ETHANETHIOL; AMIFOSTINE; ANALGESIC AGENT; CHOLINERGIC RECEPTOR BLOCKING AGENT;

ABDOMINAL CRAMP; ABDOMINAL DISTENSION; ABDOMINAL PAIN; ANUS SPHINCTER DISORDER; BLADDER DISEASE; BLOODY DIARRHEA; CANCER RADIOTHERAPY; CLINICAL TRIAL; CONCENTRATION RESPONSE; DIARRHEA; DIGESTIVE SYSTEM FISTULA; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG MECHANISM; DRUG METABOLISM; GASTROINTESTINAL OBSTRUCTION; GASTROINTESTINAL TOXICITY; HUMAN; INCONTINENCE; MUCOSA INFLAMMATION; MUCOSAL DISEASE; NONHUMAN; PAIN; PROSTATE CANCER; RADIATION INJURY; RADIATION PROTECTION; RECTUM CANCER; RECTUM DISEASE; RECTUM HEMORRHAGE; RECTUM ULCER; REVIEW; SIGMOIDOSCOPY; TENESMUS; URINARY TRACT DISEASE;

EID: 33751186094     PISSN: 15432912     EISSN: None     Source Type: Journal    
DOI: 10.3816/SCT.2006.n.028     Document Type: Review

References (37)

1. Boersma LJ, van den Brink M, Bruce AM, et al. Estimation of the incidence of late bladder and rectum complications after high-dose (70-78 Gy) conformal radiotherapy for prostate cancer, using dose-volume histograms. Int J Radiat Oncol Biol Phys 1998; 41:83-92.
2. Emami B, Lyman J, Brown A, et al. Tolerance of normal tissue to therapeutic irradiation. Int J Radiat Oncol Biol Phys 1991; 21:109-122.
3. Lyman JT. Complication probability as assessed from dose-volume histograms. Radiat Res 1985; 104:13-19.
4. Kutcher GJ, Burman C. Calculation of complication probabilities factors f or non-uniform normal tissue irradiation: the effective volume method. It J Radiat Oncol Biol Phys 1989; 16:1623-1630.
5. Lebesque JV, Bruce AM, Kroes APG, et al. Variation in volumes, dose volume histograms, and estimated normal tissue complication probabilities of rectum and bladder during conformal radiotherapy of T3 prostate cancer. Int J Radiat Oncol Biol Phys 1995; 33:1109-1119.
6. Hovdenak N, Fajardo LF, Hauer-Jensen M. Acute radiation proctitis: a sequential clinicopathologic study during pelvic radiotherapy. Int J Radiat Oncol Biol Phys 2000; 48:1111-1117.
7. Zimmermann FB, Feldmann HJ. Radiation proctitis. Clinical and pathological manifestations, therapy and prophylaxis of acute and late injurious effects of radiation on the tectal mucosa. Strahlenther Onkol 1998; 174(suppl 3):85-89.
8. Shaw LM, Turrisi AT, Glover DJ, et al. Human pharmacokinetics of WR-2721. Int J Radiat Oncol Biol Phys 1986; 12:1501-1504.
9. Calabro-Jones PM, Aguilera JA, Ward JF, et al. Uptake of WR-2721 derivatives by cells in culture: identification of the transported form of the drug. Cancer Res 1988; 48:3634-3640.
10. Schuchter LM, Glick J. The current status of WR-2721 (amifostine): a chemotherapy and radiation therapy protector. Biologic Ther Cancer 1993; 3:1-10.
11. Yuhas JM. Active versus passive absorption kinetics as the basis for selective protection of normal tissues by S-2-(3-aminopropylamino)- ethylphosphorothioic acid. Cancer Res 1980; 40:1519-1524.
12. Brizel DM, Wasserman TH, Henke M, et al. Phase III randomized trial of amifostine as a radioprotector in head and neck cancer. J Clin Oncol 2000; 18:3339-3345.
13. Hensley ML, Schuchter LM, Lindley C, et al. American Society of Clinical Oncology clinical practice guidelines for the use of chemotherapy and radiotherapy protectants. J Clin Oncol 1999; 17:3333-3355.
14. Liu T, Liu Y, He S, et al. Use of radiation with or without WR-2721 in advanced rectal cancer. Cancer 1992; 69:2820-2825.
15. Dunst J, Semlin S, Pigorsch S, et al. Intermittent use of amifostine during postoperative radiochemotherapy and acute toxicity in rectal cancer patients. Strahlenther Onkol 2000; 176:416-421.
16. Kligerman MM, Liu T, Liu Y, et al. Interim analysis of a randomised trial of radiation therapy of rectal cancet with/without WR-2721. Int J Radiat Oncol Biol Phys 1992; 22:799-802.
17. Kouvaris J, Kouloulias V, Kokakis J, et al. Cytoprotective effect of amifostine in fadiation-induced acute mucositis - a retrospective analysis. Onkologie 2002; 25:364-369.
18. Ben-Josef E, Han S, Tobi M, et al. A pilot study of topical intrarectal application of amifostine for prevention of late radiation rectal injury. Int J Radiat Oncol Biol Phys 2002; 53:1160-1164.
19. Kouvaris J, Kouloulias V, Malas E, et al. Amifostine as radioprotective agent for the mucosa of the rectum in pelvic irradiated tumors; a phase II randomized study using toxicity scales and rectosigmoidoscopy. Strahlenther Onkol 2003; 179:167-174.
20. Muller AC, Pigorsch S, Beyer C, et al. Radioprotective effects of amifostine in vitro and in vivo measured with the comet assay. Strahlenther Onkol 2004; 180:517-525.
21. Athanassiou H, Antonadou D, Coliarakis N, et al. Protective effect of amifostine during fractionated radiotherapy in patients with pelvic carcinomas: results of a randomized trial. Int J Radiat Oncol Biol Phys 2003; 56:1154-1160.
22. Kouloulias VE, Kouvaris JR, Pissakas G, et al. A phase II randomized study of topical intrarectal administration of amifostine for the prevention of acute radiation-induced rectal toxicity. Strahlenther Onkol 2004; 180:557-562.
23. Kouloulias VE, Kouvaris JR, Pissakas G, et al. A phase II multicenter randomized study of amifostine for the prevention of acute radiation rectal toxicity: topical intrarectal versus subcutaneous application. Int J Radiat Oncol Biol Phys 2005; 62:486-493.
24. Montana GS, Anscher MS, Mansbach CM II, et al. Topical application of WR-2721 to prevent radiation-induced proctosigmoiditis. A phase I/II trial. Cancer 1992; 69:2826-2830.
25. Ben-Josef E, Mesina J, Shaw LM, et al. Topical application of WR-2721 achieves high concentrations in the rectal wall. Radiat Res 1995; 143:107-110.
26. Ben-Josef E, Han S, Tobi M, et al. Intrarectal application of amifostine for the prevention of radiation-induced rectal injury. Semin Radiat Oncol 2002; 12(suppl 1):81-85.
27. Jensen DM, Machicado AG, Cheng S, et al. A randomised prospective study of endoscopic bipolar electrocoagulation and heater probe treatment of chronic rectal bleeding from radiation telangiectasia. Gastrointest Endosc 1997; 45:20-25.
28. Wachter S, Gerstner N, Goldner G, et al. Endoscopic scoring of late rectal mucosa after conformal radiotherapy for prostatic carcinoma. Radiotber Oncol 2000; 54:11-19.
29. Cox JD, Stetz J, Pajak TF. Toxicity criteria of the Radiation Therapy Oncology Group (RTOG) and the European Organization for Research and Treatment of Cancer (EORTC). Int J Radiat Oncol Biol Phys 1995; 31:1341-1346.
30. World Health Organization: Handbook for Reporting Results of Cancer Treatment. Geneva, Switzerland; World Health Organization: 1979.
31. LENT SOMA tables. Radiother Oncol 1995; 35:17-60.
32. Crespi M, Delvaux M, Schaprio M, et al. Working party report by the committee for minimal standards of terminology and documentation in digestive endoscopy of the European society of gastrointestinal endoscopy. Minimal standard terminology for a computerized endoscopic data base. Ad hoc task force of the committee. Am J Gastroenterol 1996; 91:191-216.
33. Martinez MN, Jackson AJ. Suitability of various noninfinity area under the plasma concentration-time curve (AUC) estimates for use in bioequivalence determinations: relationship to AUC from zero to time infinity (AUCO-INF). Pharm Res 1991; 8:512-517.
34. Siegel S, Castellan NJ Jr. Nonparametric Statistics for the Behavioral Sciences. 2nd ed. Boston, MA: McGraw Hill College Div; 1988.
35. Hovdenak N, Fajardo LF, Hauer-Jensen M. Acute radiation proctitis: a sequential clinicopathologic study during pelvic radiotherapy. Int J Radiat Oncol Biol Phys 2000; 48:1111-1117.
36. Jensen DM, Machicado AG, Cheng S, et al. A randomised prospective study of endoscopic bipolar electrocoagulation and heater probe treatment of chronic rectal bleeding from radiation telangiectasia. Gastrointest Endosc 1997; 45:20-25.
37. Wachter S, Gerstner N, Goldner G, et al. Endoscopic scoring of late rectal mucosa after conformal radiotherapy for prostatic carcinoma. Radiother Oncol 2000; 54:11-19.